Jasper Therapeutics, Inc. (JSPR)
NASDAQ: JSPR · Real-Time Price · USD
0.5809
+0.0108 (1.89%)
At close: Sep 16, 2026, 4:00 PM EDT
0.5794
-0.0015 (-0.26%)
After-hours: Sep 16, 2026, 4:25 PM EDT
Company Description
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States.
The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells.
It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma.
Jasper Therapeutics, Inc. was founded in 2018 and is headquartered in Redwood City, California.
Jasper Therapeutics, Inc.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Jeetinder Mahal |
Contact Details
Address: 2200 Bridge Pkwy, Suite 102 Redwood City, California 94065 United States | |
| Phone | 650 549 1400 |
| Website | jaspertx.com |
Stock Details
| Ticker Symbol | JSPR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1788028 |
| CUSIP Number | 471871202 |
| ISIN Number | US4718712023 |
| Employer ID | 84-2984849 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jeetinder Singh Mahal M.B.A. | President, Chief Executive Officer and Director |
| Thomas G. Wiggans | Executive Chairman |
| Dr. Judith Anne Shizuru M.D., Ph.D. | Co-Founder, Member of Scientific Advisory Board and Director |
| Herbert C. Cross CPA | Chief Financial Officer and Corporate Secretary |
| Matthew E. Ros | Chief Operating Officer |
| Alex Gray | Head of Investor Relations |
| Matthew Ford | Senior Vice President of Human Resources |
| Dr. Gregory F. Keenan M.D. | Chief Medical Officer |
| Dr. Wenru Song M.D., Ph.D. | Executive Vice President and Head of Research & Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 4, 2026 | DEF 14A | Other definitive proxy statements |
| Aug 26, 2026 | 8-K | Current Report |
| Aug 24, 2026 | PRE 14A | Other preliminary proxy statements |
| Aug 17, 2026 | SCHEDULE 13G | Filing |
| Aug 14, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 10-Q | Quarterly Report |
| Aug 5, 2026 | D | Notice of Exempt Offering of Securities |
| Aug 3, 2026 | 8-K | Current Report |
| Jul 31, 2026 | 8-K | Current Report |
| Jul 20, 2026 | SCHEDULE 13D/A | Filing |